March 29 (Reuters) - TG Therapeutics Inc :
* TG THERAPEUTICS COMPLETES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR UBLITUXIMAB IN COMBINATION WITH UKONIQ™(UMBRALISIB) AS A TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
* TG THERAPEUTICS COMPLETES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR UBLITUXIMAB IN COMBINATION WITH UKONIQ™(UMBRALISIB) AS A TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* TG THERAPEUTICS COMPLETES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR UBLITUXIMAB IN COMBINATION WITH UKONIQ™(UMBRALISIB) AS A TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
* TG THERAPEUTICS COMPLETES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR UBLITUXIMAB IN COMBINATION WITH UKONIQ™(UMBRALISIB) AS A TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)